Prosecution Insights
Last updated: November 04, 2026
Application No. 18/843,522

COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING PERIODONTAL DISEASES

Non-Final OA §102§103
Filed
Mar 11, 2025
Priority
Mar 04, 2022 — RE 10-2022-0028210 +1 more
Examiner
HOFFMAN, SUSAN COE
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nutracore Co. Ltd.
OA Round
1 (Non-Final)
54%
Grant Probability
Moderate
1-2
OA Rounds
1y 3m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
591 granted / 1091 resolved
-5.8% vs TC avg
Strong +26% interview lift
Without
With
+25.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
65 currently pending
Career history
1175
Total Applications
across all art units

Statute-Specific Performance

§101
10.5%
-29.5% vs TC avg
§103
35.5%
-4.5% vs TC avg
§102
15.2%
-24.8% vs TC avg
§112
27.6%
-12.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1091 resolved cases

Office Action

§102 §103
DETAILED ACTION 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 2. The preliminary amendment has been received and entered. 3. Claims 1-16 are currently pending. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. 4. Claim(s) 1, 7, 9-11 is/are rejected under 35 U.S.C. 102(a)(a) as being anticipated by Zhou (CN 113925154 – English translation). This reference teaches a food composition (which reads on a pharmaceutical) comprising Pericarpium Zanthoxyli (sancho as defined by applicant on page 2 of the specification) and wasabi leaf. The ingredients are mixed with juices (see English abstract). This would create an extract of the ingredients. The reference does not teach that the composition is used for the same purposes as claimed by applicant. However, a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. 5. Claim(s) 1-4, 6, 7, and 9-16 is/are rejected under 35 U.S.C. 103 as being unpatentable over KR 1020030064902 (English translation provided by applicant in the IDS filed September 3, 2024) and KR 102006083915 (English translation provided by applicant in the IDS filed September 3, 2024). KR ‘902 teaches a method for treating periodontal disease using a composition comprising wasabi leaf extracts. The extract is made using ethanol. In addition, the composition is formulated as a pharmaceutical or toothpaste (see paragraphs 1, 5, 8, and 24). KR ‘915 teaches a method for treating periodontal disease (including gingivitis and periodontitis) using a composition comprising sancho (Zanthoxylum schinifolium) extract. The extract is made using ethanol or aqueous ethanol. The composition is formulated as a toothpaste, pharmaceutical, or cream (see paragraphs 1, 2, 12-19, 34 and 42). These references show that it was well known in the art prior to the effective filing date of the invention to use the claimed ingredients in compositions that treat periodontal disease. It is well known that it is prima facie obvious to combine two or more ingredients each of which is taught by the prior art to be useful for the same purpose in order to form a third composition which is useful for the same purpose. The idea for combining them flows logically from their having been used individually in the prior art. Based on the disclosure by these references that these substances are used in compositions to treat periodontal disease, an artisan of ordinary skill would have a reasonable expectation that a combination of the substances would also be useful in creating compositions to treat periodontal disease. Therefore, the artisan would have been motivated to combine the claimed ingredients into a single composition. No patentable invention resides in combining old ingredients of known properties where the results obtained thereby are no more than the additive effect of the ingredients. See MPEP section 2144.06, In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980), Ex parte Quadranti, 25 USPQ2d 1071 (Bd. Pat. App. & Inter. 1992). The references do not specifically teach adding the ingredients together in the amounts claimed by applicant. However, as discussed in MPEP section 2144.05(II)(A), “Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. ‘[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.’ In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955).” The references teach the use of each of the ingredients in a pharmaceutical composition. Varying the concentration of ingredients within a pharmaceutical composition is not considered to be inventive unless the concentration is demonstrated as critical. In this particular case, applicant’s specification asserts that the combination of the ingredients produces a synergistic result. However, the results shown in the specification are not commensurate in scope with the broadly claimed invention. In addition, it is unclear if the results are synergistic rather than an expected additive effect. Thus, this optimization of ingredient concentration would have been obvious before the effective filing date of applicant’s claimed invention. 6. Claim(s) 5 and 8 is/are rejected under 35 U.S.C. 103 as being unpatentable over KR 1020030064902 (English translation provided by applicant in the IDS filed September 3, 2024) and KR 102006083915 (English translation provided by applicant in the IDS filed September 3, 2024) as applied to claims 1-4, 6, 7, and 9-16 above, and further in view of Park (Kor. J. Hort. Sci. Technol. (2006), vol. 24, no. 4, pp. 480-487) and Fang (Bulletin of the Korean Chemical Society (2010), vol. 32, no. 4, 5 pages). The teachings of KR ‘902 and KR ‘915 are discussed above. The references do not discuss the concentrations of sinigrin in the extracts. However, each reference teaches that the effectiveness of the extracts in the treatment of periodontal disease is based on their antibacterial activity (see paragraph 7 of KR ‘902 and paragraph 4 of KR ‘915). Park teaches that wasabi leaves contain sinigrin as an active antimicrobial component (see abstract). In addition, Fang teaches that Z. schinifolium (sancho) also contains sinigrin (see column 1 of page 1). Thus, an artisan of ordinary skill would reasonably expect that the extracts of KR ‘902 and KR ‘915 would show improved treatment of periodontal disease if the extracts were modified to obtain an optimal concentration of sinigrin as an active antibacterial agent. This reasonable expectation of success would have motivated the artisan to modify the extracts of KR ‘902 and KR ‘915 to obtain an optimized concentration of sinigrin. 7. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Hoffman whose telephone number is (571)272-0963. The examiner can normally be reached M-Th 8:30am - 5:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached at 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUSAN HOFFMAN/Primary Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Mar 11, 2025
Application Filed
Oct 30, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779000
Processes for Extracting Muscimol from Amanita Muscaria
3y 1m to grant Granted Nov 03, 2026
Patent 12766178
SKIN CLARIFIER
5y 0m to grant Granted Oct 20, 2026
Patent 12766176
DEBITTERING KUDINGCHA EXTRACT, PREPARATION METHOD AND FINGERPRINT DETECTION METHOD THEREOF
3y 8m to grant Granted Oct 20, 2026
Patent 12766180
Fagopyrum Nutraceutical Compositions
2y 7m to grant Granted Oct 20, 2026
Patent 12758602
ANTI-INFLAMMATORY COMPOSITION COMPRISING EPIMENDIUM KOREANUM NAKAI, POLYGALA TENUIFOLIA WILD, AND POLYPORUS UMBELLATUS FRIES EXTRACTS OR MIXTURE THEREOF AS ACTIVE INGREDIENT
3y 1m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
54%
Grant Probability
80%
With Interview (+25.7%)
2y 11m (~1y 3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1091 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month